Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma Journal Article


Authors: Basaran, D.; Bruce, S.; Aviki, E. M.; Mueller, J. J.; Broach, V. A.; Cadoo, K.; Soslow, R. A.; Alektiar, K. M.; Abu-Rustum, N. R.; Leitao, M. M. Jr
Article Title: Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma
Abstract: Objectives: The objective of our study was to assess survival among patients with uterine serous carcinoma (USC) undergoing sentinel lymph node (SLN) mapping alone versus patients undergoing systematic lymphadenectomy (LND). Methods: We retrospectively reviewed patients undergoing primary surgical treatment for newly diagnosed USC at our institution from 1/1/1996-12/31/2017. Patients were assigned to either SLN mapping alone (SLN cohort) or systematic LND without SLN mapping (LND cohort). Progression-free (PFS) and overall survival (OS) were estimated using Kaplan-Meier method, compared using Logrank test. Results: 245 patients were available for analysis: 79 (32.2%) underwent SLN, 166 (67.7%) LND. 132 (79.5%) in the LND cohort had paraaortic LND (PALND) versus none in the SLN cohort. Median age: 66 and 68 years in the SLN and LND cohorts, respectively (p>0.05). Proportion of stage I/II disease: 67.1% (n = 53) and 64.5% (n = 107) in the SLN and LND cohorts, respectively (p>0.05). Median follow-up: 23 (range, 1–96) and 66 months (range, 4–265) in the SLN and LND cohorts, respectively (p < 0.001). Two-year OS in stage I/II disease (n = 160, 60.1%): 96.6% (SE ± 3.4) and 89.6% (SE ± 2.2) in the SLN and LND cohorts, respectively (p = 0.8). Two-year OS in stage III disease (n = 77): 73.6% (SE ± 10.2) and 77.3% (SE ± 5.8) in the SLN and LND cohorts, respectively (p = 0.8). Conclusions: SLN mapping alone and systematic LND yielded similar survival outcomes in stage I-III USC. In our practice, the SLN algorithm has replaced systematic LND as the primary staging modality in this setting. © 2019 Elsevier Inc.
Keywords: adult; aged; major clinical study; overall survival; clinical feature; paclitaxel; cancer staging; follow up; endometrial cancer; lymph node dissection; sentinel lymph node; sentinel lymph node biopsy; lymphadenectomy; carboplatin; progression free survival; retrospective study; uterus carcinoma; uterine serous carcinoma; human; female; priority journal; article
Journal Title: Gynecologic Oncology
Volume: 156
Issue: 1
ISSN: 0090-8258
Publisher: Elsevier Inc.  
Date Published: 2020-01-01
Start Page: 70
End Page: 76
Language: English
DOI: 10.1016/j.ygyno.2019.10.005
PUBMED: 31739992
PROVIDER: scopus
PMCID: PMC6980657
DOI/URL:
Notes: Article -- Export Date: 3 February 2020 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Kaled M Alektiar
    271 Alektiar
  2. Mario Leitao
    380 Leitao
  3. Robert Soslow
    721 Soslow
  4. Karen Anne Cadoo
    72 Cadoo
  5. Jennifer Jean Mueller
    61 Mueller
  6. Vance Andrew Broach
    26 Broach
  7. Emeline Mariam Aviki
    14 Aviki
  8. Shaina Bruce
    2 Bruce